The global high-throughput screening market mainly comprises of target identification & validation, efficacy & safety screening, and monitoring of cell-based activity. High-throughput screening (HTS) is a popular approach to target validation, as it allows the assaying of a large number of potential biological modulators against a chosen set of defined targets. The screening test uses reflectivity measurements, quantifying the extent of binding of any logical entity (e.g. proteins, cells, animal embryo) with the base compound in the wells. The HTC technique can examine/screen 300,000 compounds a day, so it takes only a few weeks to screen millions of substances. The global high-throughput screening market is mainly driven by the adoption of open innovation models by pharmaceutical companies to increase the use of high-throughput screening. Certain other factors include increasing drug discovery initiatives by academic and government institutions to boost the demand for high-throughput screening products, and huge capital investments in high-throughput screening technology by major firms, such as PerkinElmer, Beckman Coulter, and Tecan Group, among others. Private equity firms and venture capitalists are increasingly investing in the HTS market in countries, such as India, China, and Japan.
Drivers & Restraints
The increasing demand in research, huge capital investments in the HTS technology, the rise in outsourced drug discovery services, and increasing utilization rate of high-throughput screening technologies by pharmaceutical companies are key factors propelling the growth of the market. However, the capital-intensive nature, need for extensive automation techniques, and high regulatory intervention and costs are turning out to be restraints for the market. Many marketed drugs went off-patent in 2012.
The global HTS market is segmented into:
The technology segment is further categorized into ultra-high-throughput screening (uHTS), cell-based assay, lab-on-a-chip, label-free technology, and bioinformatics. The cell-based assay segment accounted for the largest share in 2013, followed by the lab-on-a-chip segment. The application segment of the high-throughput screening comprises of target identification, primary screening, toxicology, and stem cell biology. Many new innovative techniques such as drop-based microfluidics, silicon sheet, and microfluidic arrays are propelling the market growth to a great extent. By product, the HTS market is segmented into instruments, consumable/reagent, and software & service. The end-user segment categorizes the high-throughput screening market into pharmaceutical, biotechnology, academia & government organizations, and contract research organizations.
Geographically, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa and Latin America. The United States represents the largest portion of the global HTS market, worldwide. The APAC region, especially China and India, provide immense growth opportunities for the high-throughput screening market during the forecast period, as it accounts for more than half of the world’s total population. An increasing development and production of vaccines, drugs, & new biologics, growing government and corporate investments in the biotechnology and pharmaceutical sector, rising median age of the population, and the presence of high unmet market demand are factors contributing to the growth of the HTS market in this particular geographical domain.
The current market lacks extensive capital and heavy VC and other funding sources; hence introducing innovative products to tap the emerging economies would be a great opportunity for the market.
The key players in the market are:
Agilent Technologies, Inc (U.S.)
Beckman Coulter, Inc (U.S.), (a subsidiary of Danaher Corporation)
Sigma-Aldrich Corporation (U.S.)
Accelrys, Inc (USA)
Aurora Biomed, Inc (Canada)
Tecan Group (Switzerland)
Market analysis for the global HTS market, with region specific assessments and competition analysis.
Market definition along with the identification of key drivers, restraints opportunities and challenges.
Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
Extensively researched competitive landscape section with company profiles of key players with the analysis of their current strategic interests and key financial information.
Identification and analysis of the macro and micro factors that affect the global HTS market.
Insights of the market in the regions that have the highest potential for growth and to also identify the markets that are still untapped.
1.1 Study deliverables
1.2 Market Definition
1.3 General Study Assumptions
1.4 Report Description
2. Research Methodology
2.2 Analysis Methodology
2.3 Study timeline
2.4 Study Phases
2.4.1 Secondary Research
2.4.2 Discussion Guide
2.4.3 Market Engineering & Econometric Model
2.4.4 Expert Validation
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry trends
5.1 Current Market Scenario
5.2 Porter's Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat to new entrants
5.2.4 Threat to substitute products and services
5.2.5 Competitive Rivalry within the industry
6. Market Drivers, Restraints, Opportunities, and challenges Analysis
6.1 Market Drivers
6.1.1 Increasing demand in research
6.1.2 Increasing investment by private equity firms and venture capitalists
6.1.3 High rate of utilization of high-throughput screening technologies by pharmaceutical companies
6.1.4 Rise in outsourced drug discovery services
6.2 Market Restraints
6.2.1 Capital intensive nature - High QC
6.2.2 Need for extensive automation techniques
6.2.3 High regulatory intervention and cost
6.3 Market Opportunities
6.3.1 Open Access HTS laboratories
6.4 Market Challenges
6.4.1 Economic slowdown on HTS outsourcing
6.4.2 High Capital and Automation investment
7. Market Segmentation
7.1 By Technology
184.108.40.206 2D Cell Culture
220.127.116.11 3D Cell Culture
18.104.22.168.1 Scaffold-Based Technology
22.214.171.124.1.1.1 Animal-Derived Hydrogels
126.96.36.199.1.1.3 Synthetic Hydrogels
188.8.131.52.1.2 Inert Matrix/Solid Scaffolds
184.108.40.206.2 Scaffold-Free Technology
220.127.116.11.2.2 Hanging-Drop Plates
18.104.22.168.2.3 Ultra-Low Binding Plates
22.214.171.124.2.4 Other Scaffold-Free Technologies
126.96.36.199 Perfusion Cell Culture
7.1.3 Ultra-High-Throughput Screening
7.1.4 Label-Free Technology
7.2 BY Application
7.2.1 Target Identification
188.8.131.52 Small compound
7.2.2 Primary Screening
184.108.40.206 Cancer Agents
220.127.116.11 Anti- Viral
7.2.4 Stem Cell Biology
7.3 By Products
7.3.3 Software & service
7.4 By End-Users
7.4.3 Academia & Government
7.4.4 Contract Research Organization
8. By Geography
8.1 North America
8.2.8 Rest of Europe
8.3.4 South Korea
8.3.5 Australia & New Zealand
8.3.6 Rest of Asia-Pacific
8.4 Middle East & Africa
8.4.2 South Africa
8.4.3 Rest of MENA
8.5 South America
8.5.3 Rest of South America
9. Competitive Landscape
9.1 Mergers and Acquisition analysis
9.2 Collaboration and partnerships
9.3 New product launches
10. Key Vendor Analysis
10.1 Agilent Technologies Inc.
10.3 Beckman Coulter Inc. (a subsidiary of Danaher Corporation)
10.4 Sigma-Aldrich Corporation
10.5 Accelrys Inc.
10.6 Aurora Biomed Inc.
10.7 Tecan Group
11. Analyst Outlook for Investment Opportunities
12. Future Outlook of the Market
- Agilent Technologies Inc. (U.S.)
- Perkinelmer (U.S.)
- Beckman Coulter Inc. (U.S.)
- (A Subsidiary of Danaher Corporation)
- Sigma-Aldrich Corporation (U.S.)
- Accelrys Inc. (Usa)
- Aurora Biomed Inc. (Canada)
- Tecan Group (Switzerland)